Overview

A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease

Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
A long-term extension study to evaluate the safety, tolerability, and efficacy of AL002 in participants with Early Alzheimer's Disease.
Phase:
Phase 2
Details
Lead Sponsor:
Alector Inc.
Collaborator:
AbbVie